Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AbbVie extends Pharmacyclics offer to give FTC more time

This article was originally published in Scrip

Executive Summary

AbbVie has extended the deadline of its exchange offer to acquire the shares of Pharmacyclics to 1 May. It also said it had withdrawn its Hart-Scott-Rodino filing and would resubmit it on 21 April, from when a new 30 calendar day HSR waiting period would commence. This was to provide US Federal Trade Commission with more time to review the proposed deal. This type of "pull and refile" procedure, in which a company withdraws its application and resubmits it within two working days, enables companies to provide additional information without having to be subject to a formal FTC 'second request', which is a more time-consuming and expensive way of giving the FTC extra time. AbbVie said it and Pharmacyclics "continue to work cooperatively with the FTC staff in their review". It expects the deal to close in the second quarter of 2015. AbbVie announced the $21bn cash and shares transaction on 4 March. As of 4pm EST on 17 April, around 47.5m Pharmacyclics shares (around 62% of total outstanding stock) had been validly tendered to the offer and not withdrawn.

You may also be interested in...

Big Pharma’s Aging Antibodies Cling To Their Crowns

The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?

Novartis To Pay $9.7bn For The Medicines Company

Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.

Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates

Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts